PharmaCyte Bio rises on biocompatibility results for cancer therapy

Pharmacyte Biotech

16/09/2021 17:05

** Shares of drug developer  PMCB.O  rise 5.9% to $3.54
    ** PMCB reports positive results from a biocompatibility
study of its experimental CypCaps capsules for pancreatic cancer
 urn:newsml:reuters.com:*:nBwbhKVyRa
    ** Lab study shows the capsule material does not activate a
part of the body's immune system which targets foreign
substances, says co
    ** Says other studies by third-party contract research
organizations are also ongoing
    ** Biocompatibility studies assess the response of the body
when it comes in contact with the components of a medical
product
    ** Stock down 64.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))